Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FARGO: Faecal Microbiota Transplantation in Primary Sclerosing Cholangitis
NCT06286709Phase 2Recruiting
- Sponsor
- University of Birmingham
- Start
- Mar 2024
- Primary completion
- Sep 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic fecal microbiota in Primary Sclerosing Cholangitis (PSC), inflammatory bowel disease (IBD), sponsored by University of Birmingham. Started Mar 2024; status: recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Primary Sclerosing Cholangitis (PSC)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT06286709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06286709.